Ebola vaccine

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Jiangsu Province Centers for Disease Control and Prevention

Conditions

Ebola DiseaseEbola Virus DiseaseMarburg Virus Disease

Phase 1

Evaluating an Ebola and a Marburg Vaccine in Uganda

CompletedNCT00997607

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Virus Disease, Marburg Virus Disease

Start: 2010-02-28End: 2012-04-30Updated: 2013-01-28

Phase 2

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

CompletedNCT02575456

Jiangsu Province Centers for Disease Control and PreventionEbola Disease

Start: 2015-10-31End: 2016-07-31Updated: 2016-09-01

Related Papers

Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.

2024-03-2910 citations

Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.

2014-12-2391 citations